El-Sayed et al. have demonstrated that anti-EGFR-antibody-conjugated gold NPs have a distinct difference in the distribution that conjugated NPs bind uniformly and specifically to the surface of the cancer cells via target cell recognition and bind nonspecifically and randomly to noncancerous cells [28]. This evidence concerns the gene EGFR and cancer.